title: Simultaneous mold infections in an orthotopic heart transplant recipient.
abstract: Simultaneous mold infections in heart transplant recipients have not been previously reported. Here we describe early onset post-transplant pulmonary aspergillosis and cutaneous zygomycosis in a 46-year-old heart transplant recipient who was also treated with basiliximab. Along with surgical debridement, medical treatment of his cutaneous abdominal wall zygomycosis at the former left ventricular assist device driveline site with liposomal amphotericin B and voriconazole also led to cure of his pulmonary aspergillosis.
authors.affiliation: Section of Infectious Diseases, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA.
authors.forename: H
authors.initials: H
authors.lastname: Clauss
authors.forename: R
authors.initials: R
authors.lastname: Samuel
mesh_terms: D000666:Amphotericin B / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use; D001232:Aspergillus fumigatus; D000077552:Basiliximab; D002311:Cardiomyopathy, Dilated / Q000601:surgery; D003646:Debridement; D003881:Dermatomycoses / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D016027:Heart Transplantation / Q000009:adverse effects*; D006801:Humans; D016867:Immunocompromised Host / Q000187:drug effects; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009091:Mucormycosis / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D016459:Prosthesis-Related Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D055732:Pulmonary Aspergillosis / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000009:adverse effects*; D012233:Rhizopus; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use; D065819:Voriconazole
chemical_list: D000911:Antibodies, Monoclonal; D000935:Antifungal Agents; D007166:Immunosuppressive Agents; D011743:Pyrimidines; D011993:Recombinant Fusion Proteins; D014230:Triazoles; C068538:liposomal amphotericin B; D000666:Amphotericin B; D000077552:Basiliximab; D065819:Voriconazole